.jpg?format=webp&width=780)
To evaluate the efficacy and safety of DBPR108 (prusogliptin), a novel dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor, as add‐on therapy in patients with type 2 diabetes mellitus (T2DM) that is inadequately controlled with metformin. A higher proportion of patients achieved an HbA1c ≤6.5% (19.7% vs. 8.5%) and HbA1c ≤7.0% (50.0% vs. 21.1%) at week 24 in the DBPR108+metformin group. DBPR108, as an add‐on therapy to metformin offered a significant improvement in glycemic control, was superior to metformin monotherapy (placebo) and was safe and well‐tolerated in T2DM patients inadequately controlled with metformin.
Like
Save
Share